All In Biotech

Drug Trial Radar · NCT05973149

Trial of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer

Tolerance, Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Aug 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

108

Planned (sponsor's estimate)

Start

Aug 31, 2023

Primary completion

Aug 31, 2025

Study completion Jan 1, 2026

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Aug 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the tolerance, safety, pharmacokinetics, and preliminary anti-tumor activity of QLH12016 in patients with metastatic castration resistant prostate cancer

Conditions

  • Prostate Cancer

Interventions

  • QLH12016Drug

    according to the scheme description

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Arm A: Incidence of Dose Limiting ToxicitiesTime frame: 28 Days
  2. Arm A:Maximum Tolerated DoseTime frame: 28 Days
  3. Arm A:Recommended Phase 2 DoseTime frame: 28 Days
  4. Arm A:AETime frame: 20 weeks
  5. Arm A:SAETime frame: 20 weeks
  6. Arm B-D:PSA Response RateTime frame: 20 weeks
  7. Arm B-D:Objective Response RateTime frame: 20 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Department of Urology, Peking University First Hospital

    Beijing, Beijign, China

  • Department of Urology, Drum Tower Hospital, Nanjing University School of Medicine

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.